

## PRESS-RELEASE – FOR IMMEDIATE RELEASE

### Calmino and Ewopharma join up to treat Irritable Bowel Syndrome (IBS)

**Schaffhausen, Switzerland, 29.04.22** - IBS affects 10-15% of the European population, but less than 2% are correctly diagnosed. Many individuals have been suffering for many years. IBS is a chronic disorder which strongly affects the quality of one's life. A group of symptoms occur together, including repeated abdominal pain and changes in bowel movements, which may be diarrhoea, constipation - or both. Other typical symptoms are bloating, distension, flatulence and borborygmi. As the main cause of IBS is not definitely known, treatment focuses on the symptoms.

#### **PROIBS® - to help patients treat IBS symptoms**

PROIBS® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). PROIBS® contains AVH200®, derived from the plant *Aloe barbadensis* Mill. AVH200® has gel forming components which support the intestinal mucosal barrier.

As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use – as PROIBS® is. The product is safe, and no interactions with other medications are known.

Science-driven innovative Calmino group AB, the developer of PROIBS®, conducted a usability study among 1.003 users. PROIBS® was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else. To learn more please check: [www.proibs.eu](http://www.proibs.eu).



Calmino group AB (Gothenburg, Sweden) and Ewopharma (Schaffhausen, Switzerland) have entered into an exclusive distribution agreement for the territories of Czech Republic and Slovakia in order to launch PROIBS® for the treatment of symptoms related to IBS. This agreement includes all marketing and sales activities of PROIBS® as of April 2022.

Simone Thomas, Senior Product Manager at Ewopharma Group comments: «With PROIBS®, we are able to provide an innovative and certified medical device for the treatment of symptoms related to IBS. The product has been on the Swedish pharmacy market for more than a decade. Because it is recommended by physicians and dietitians, we can promote PROIBS® with absolute confidence. We are looking forward to offering a solution that truly improves the liveability of the affected people.»

Tobias Kisker, CEO and founder of Calmino group AB, is pleased to start a long and successful collaboration with Ewopharma. «The Calmino team is happy to work with a well-established, experienced, and professional company like Ewopharma. We see the Czech Republic and Slovakia as a first important introduction to other Central Eastern European markets.»

Page 2 of 2

### **About Calmino AB**

Calmino group AB is a Swedish, science-driven innovative healthcare company with focus on gut health. Their vision is to successfully contribute towards improving health and well-being for people with digestive and gastrointestinal disorders. Calmino was founded in 2003. In 2010, a product for the dietary management of IBS under the brand “PROIBS®” was launched. After many successful years on the market in various pharmacies in Sweden and other European countries, the product was recently certified as a medical device for the treatment of IBS symptoms. For more information visit [www.calmino.com](http://www.calmino.com)

### **About Ewopharma AG**

Ewopharma AG, headquartered in Schaffhausen (Switzerland), is a pharmaceutical marketing company focused on Central Eastern Europe and Switzerland. With more than 60 years presence in the region, Ewopharma has extensive knowledge of these markets and enjoys a privileged position in the area. The company covers all aspects of market access and commercialisation of ethical pharmaceutical and consumer health products. Further information is available at [www.ewopharma.com](http://www.ewopharma.com).

### **For further information, please contact:**

Calmino group AB  
Tobias Kisker  
Founder and CEO  
Tel.: +46 705 88 14 53  
E-Mail: [tobias.kisker@calmino.com](mailto:tobias.kisker@calmino.com)

or

Ewopharma AG  
Simone Thomas  
Senior Product Manager Ewopharma Group  
Tel.: +41 52 633 09 99  
E-mail: [s.thomas@ewopharma.com](mailto:s.thomas@ewopharma.com)